LTPA2017019I1 - Žmogaus antikūnai, pasižymintys dideliu giminingumu PCSK9 - Google Patents
Žmogaus antikūnai, pasižymintys dideliu giminingumu PCSK9Info
- Publication number
- LTPA2017019I1 LTPA2017019I1 LTPA2017019C LTPA2017019C LTPA2017019I1 LT PA2017019 I1 LTPA2017019 I1 LT PA2017019I1 LT PA2017019 C LTPA2017019 C LT PA2017019C LT PA2017019 C LTPA2017019 C LT PA2017019C LT PA2017019 I1 LTPA2017019 I1 LT PA2017019I1
- Authority
- LT
- Lithuania
- Prior art keywords
- pcsk9
- high affinity
- human antibodies
- antibodies
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12248208P | 2008-12-15 | 2008-12-15 | |
US21056609P | 2009-03-18 | 2009-03-18 | |
US16875309P | 2009-04-13 | 2009-04-13 | |
US21813609P | 2009-06-18 | 2009-06-18 | |
US24913509P | 2009-10-06 | 2009-10-06 | |
US26177609P | 2009-11-17 | 2009-11-17 | |
PCT/US2009/068013 WO2010077854A1 (en) | 2008-12-15 | 2009-12-15 | High affinity human antibodies to pcsk9 |
Publications (2)
Publication Number | Publication Date |
---|---|
LTPA2017019I1 true LTPA2017019I1 (lt) | 2017-07-10 |
LTC2358756I2 LTC2358756I2 (lt) | 2022-04-25 |
Family
ID=41668268
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP09793408.7T LT2358756T (lt) | 2008-12-15 | 2009-12-15 | Žmogaus antikūnai, pasižymintys dideliu giminingumu pcsk9 |
LTEP16200305.7T LT3156422T (lt) | 2008-12-15 | 2009-12-15 | Didelio giminingumo žmogaus antikūnai prieš pcsk9 |
LTPA2017019C LTC2358756I2 (lt) | 2008-12-15 | 2017-06-19 | Žmogaus antikūnai, pasižymintys dideliu giminingumu pcsk9 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP09793408.7T LT2358756T (lt) | 2008-12-15 | 2009-12-15 | Žmogaus antikūnai, pasižymintys dideliu giminingumu pcsk9 |
LTEP16200305.7T LT3156422T (lt) | 2008-12-15 | 2009-12-15 | Didelio giminingumo žmogaus antikūnai prieš pcsk9 |
Country Status (43)
Families Citing this family (274)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
US20130072665A1 (en) * | 2007-08-23 | 2013-03-21 | Simon Mark Jackson | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9) |
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
MY164121A (en) | 2009-06-26 | 2017-11-30 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
PT2517556E (pt) | 2009-07-08 | 2016-01-20 | Kymab Ltd | Modelos animais e moléculas terapêuticas |
US20120204278A1 (en) | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
US8518405B2 (en) | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
IN2012DN03824A (lt) * | 2009-10-30 | 2015-08-28 | Merck Sharp & Dohme | |
AR079336A1 (es) * | 2009-12-11 | 2012-01-18 | Irm Llc | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) |
JO3274B1 (ar) | 2009-12-24 | 2018-09-16 | Regeneron Pharma | أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري |
CN102844332B (zh) * | 2010-03-11 | 2015-08-19 | 瑞纳神经科学公司 | 呈pH依赖性抗原结合的抗体 |
CA2807127C (en) * | 2010-08-02 | 2019-02-12 | Leslie S. Johnson | Covalent diabodies and uses thereof |
US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
JO3756B1 (ar) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
SG191219A1 (en) * | 2010-12-22 | 2013-07-31 | Genentech Inc | Anti-pcsk9 antibodies and methods of use |
EP2650016A1 (en) | 2011-01-28 | 2013-10-16 | Sanofi | Human antibodies to PSCK9 for use in methods of treatment based on particular dosage regimens (11565) |
MX347602B (es) * | 2011-01-28 | 2017-05-03 | Sanofi Biotechnology | Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9. |
EP2481758A1 (en) | 2011-01-28 | 2012-08-01 | Sanofi | Human antibodies to PSCK9 for use in methods of treating particular groups of subjects (11566) |
SG192945A1 (en) | 2011-02-25 | 2013-09-30 | Chugai Pharmaceutical Co Ltd | Fcgriib-specific fc antibody |
US8337530B2 (en) * | 2011-03-09 | 2012-12-25 | Zimmer Spine, Inc. | Polyaxial pedicle screw with increased angulation |
AR088782A1 (es) | 2011-04-29 | 2014-07-10 | Sanofi Sa | Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes |
JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
WO2012170807A2 (en) | 2011-06-10 | 2012-12-13 | Medimmune, Llc | Anti-pseudomonas psl binding molecules and uses thereof |
JO3412B1 (ar) | 2011-06-17 | 2019-10-20 | Regeneron Pharma | أجسام مضادة ل angptl3 واستخداماتها |
CA2840482C (en) * | 2011-07-14 | 2018-10-16 | Pfizer Inc. | Treatment with anti-pcsk9 antibodies |
AR087305A1 (es) * | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
AR087715A1 (es) | 2011-09-16 | 2014-04-09 | Lilly Co Eli | Anticuerpos anti pcsk9 y usos de los mismos |
JP6158813B2 (ja) | 2011-09-16 | 2017-07-05 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | プロタンパク質転換酵素サブチリシンケキシン−9(PCSK9)の阻害剤を投与することによってリポタンパク質(a)レベルを低下させる方法 |
BR112014006394A2 (pt) | 2011-09-19 | 2017-03-28 | Kymab Ltd | manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos |
WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
EP3939996A1 (en) | 2011-09-30 | 2022-01-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
ITPC20110013U1 (it) | 2011-10-07 | 2013-04-08 | Giovanni Merli | Struttura di protezione superiore veicoli. |
EP2776065B1 (en) * | 2011-11-07 | 2020-08-05 | MedImmune Limited | Combination therapies using anti- pseudomonas psl and pcrv binding molecules |
RU2739792C1 (ru) | 2011-11-30 | 2020-12-28 | Чугаи Сейяку Кабусики Кайся | Содержащий лекарственное средство переносчик в клетку для формирования иммунного комплекса |
US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
CA2858572C (en) | 2011-12-08 | 2023-01-17 | Amgen Inc. | Human lcat antigen binding proteins and their use in therapy |
NZ627859A (en) | 2012-01-23 | 2015-09-25 | Regeneron Pharma | Stabilized formulations containing anti-ang2 antibodies |
HRP20211541T1 (hr) * | 2012-01-31 | 2021-12-24 | Regeneron Pharmaceuticals, Inc. | Anti-asic1 antitijela i njihove upotrebe |
US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
RS59076B1 (sr) | 2012-03-16 | 2019-09-30 | Regeneron Pharma | Glodari koji eksprimiraju imunoglobulinske sekvence senzitivne na ph |
CN104302169B (zh) | 2012-03-16 | 2017-11-17 | 瑞泽恩制药公司 | 组氨酸工程改造的轻链抗体和用于生成所述抗体的经基因修饰的非人动物 |
AU2013204581B2 (en) | 2012-03-16 | 2015-06-25 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing pH-sensitive immunoglobulin sequences |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
US20130281355A1 (en) * | 2012-04-24 | 2013-10-24 | Genentech, Inc. | Cell culture compositions and methods for polypeptide production |
EA039663B1 (ru) * | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
AR091462A1 (es) * | 2012-06-15 | 2015-02-04 | Genentech Inc | Anticuerpos anti-pcsk9, formulaciones, dosificacion y metodos de uso |
EA028244B1 (ru) * | 2012-08-13 | 2017-10-31 | Ридженерон Фармасьютикалз, Инк. | АНТИТЕЛА К PCSK9 C pH-ЗАВИСИМЫМИ ХАРАКТЕРИСТИКАМИ СВЯЗЫВАНИЯ |
JO3462B1 (ar) | 2012-08-22 | 2020-07-05 | Regeneron Pharma | أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها |
DK2889377T3 (da) | 2012-08-24 | 2020-03-30 | Chugai Pharmaceutical Co Ltd | Fc?RIIb-Specifik Fc-regionsvariant |
EP2703009A1 (en) | 2012-08-31 | 2014-03-05 | Sanofi | Combination treatments involving antibodies to human PCSK9 |
EP2703008A1 (en) * | 2012-08-31 | 2014-03-05 | Sanofi | Human antibodies to PCSK9 for use in methods of treating particular groups of subjects |
EP2706070A1 (en) | 2012-09-06 | 2014-03-12 | Sanofi | Combination treatments involving antibodies to human PCSK9 |
EP4234694A3 (en) | 2012-11-21 | 2023-09-06 | Amgen Inc. | Drug delivery device |
US10766960B2 (en) | 2012-12-27 | 2020-09-08 | Chugai Seiyaku Kabushiki Kaisha | Heterodimerized polypeptide |
WO2014107657A2 (en) * | 2013-01-04 | 2014-07-10 | Kohn Kenneth I | Cholesterol-lowering compounds in combination with lipid metabolism-altering compounds of non-absorbable sugars, compounds that convert nh3 to nh4+, or hydrogen-generating compounds for the treatment of high cholesterol and inflammation |
WO2014107739A1 (en) * | 2013-01-07 | 2014-07-10 | Eleven Biotherapeutics, Inc. | Antibodies against pcsk9 |
AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
JP2016514668A (ja) * | 2013-03-15 | 2016-05-23 | アムジエン・インコーポレーテツド | プロタンパク質コンベルターゼスブチリシンケクシン9型に結合するヒト抗原結合タンパク質 |
WO2014149699A1 (en) | 2013-03-15 | 2014-09-25 | Eli Lilly And Company | Bifunctional protein |
US10492990B2 (en) | 2013-03-15 | 2019-12-03 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
TWI580451B (zh) | 2013-03-15 | 2017-05-01 | 安美基公司 | 用於注射器之匣盒及使用具有自動注射器及匣盒之自動注射器設備之方法 |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
AU2014238267B2 (en) | 2013-03-22 | 2019-08-15 | Amgen Inc. | Injector and method of assembly |
WO2014163101A1 (ja) | 2013-04-02 | 2014-10-09 | 中外製薬株式会社 | Fc領域改変体 |
US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
TWI682780B (zh) * | 2013-05-30 | 2020-01-21 | 美商再生元醫藥公司 | 醫藥組成物用於製造治療與pcsk9功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途 |
US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
EP2810955A1 (en) | 2013-06-07 | 2014-12-10 | Sanofi | Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9 |
TW202021614A (zh) * | 2013-06-07 | 2020-06-16 | 法商賽諾菲生物技術公司 | 藉由投與pcsk9抑制劑抑制動脈粥狀硬化的方法 |
ES2901400T3 (es) * | 2013-06-07 | 2022-03-22 | Regeneron Pharma | Métodos para inhibir la ateroesclerosis administrando un inhibidor de PCSK9 |
EP2862877A1 (en) | 2013-10-18 | 2015-04-22 | Sanofi | Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9 |
CA2916259C (en) | 2013-06-28 | 2024-02-20 | Amgen Inc. | Methods for treating homozygous familial hypercholesterolemia |
CA2925723A1 (en) | 2013-10-01 | 2015-04-09 | Kymab Limited | Animal models and therapeutic molecules |
JP6846931B2 (ja) * | 2013-10-11 | 2021-03-24 | サノフィ・バイオテクノロジー | 高脂血症を処置するためのpcsk9阻害剤の使用 |
MX2016005312A (es) | 2013-10-24 | 2016-08-11 | Amgen Inc | Inyector y metodo de montaje. |
MX2016005315A (es) | 2013-10-24 | 2016-08-11 | Amgen Inc | Sistema de administracion de farmacos con control sensible a la temperatura. |
ES2864350T3 (es) * | 2013-11-12 | 2021-10-13 | Regeneron Pharma | Pautas posológicas para uso con inhibidores de PCSK9 |
EP3068803B1 (en) | 2013-11-12 | 2021-01-20 | Sanofi Biotechnology | Dosing regimens for use with pcsk9 inhibitors |
US9051378B1 (en) | 2014-07-15 | 2015-06-09 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
US9045548B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment |
US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US9023359B1 (en) | 2014-07-15 | 2015-05-05 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
DE202014010499U1 (de) | 2013-12-17 | 2015-10-20 | Kymab Limited | Targeting von humaner PCSK9 zur Cholesterinbehandlung |
US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
US9034332B1 (en) | 2014-07-15 | 2015-05-19 | Kymab Limited | Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment |
US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
CA2933960A1 (en) * | 2013-12-17 | 2015-06-25 | Aimm Therapeutics B.V. | Means and methods for counteracting myeloproliferative or lymphoproliferative disorders |
US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
US8945560B1 (en) | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US10994112B2 (en) | 2014-02-05 | 2021-05-04 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
CN106029096A (zh) | 2014-02-14 | 2016-10-12 | 瑞泽恩制药公司 | 用于治疗具有未被中等剂量他汀疗法充分控制的高胆固醇血症的患者的方法 |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
MX2016011975A (es) * | 2014-03-17 | 2016-12-05 | Sanofi Biotechnology | Metodos para reducir el riesgo cardiovascular. |
WO2015171777A1 (en) | 2014-05-07 | 2015-11-12 | Amgen Inc. | Autoinjector with shock reducing elements |
EP3143138B1 (en) | 2014-05-13 | 2022-03-23 | BioAtla, Inc. | Conditionally active biological proteins |
JP6817074B2 (ja) | 2014-06-03 | 2021-01-20 | アムジエン・インコーポレーテツド | 制御可能な薬物送達システム及び使用方法 |
WO2015200438A1 (en) * | 2014-06-24 | 2015-12-30 | Eleven Biotherapeutics, Inc. | High affinity antibodies against pcsk9 |
US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
DE202015009007U1 (de) | 2014-07-15 | 2016-08-19 | Kymab Limited | Targeting von humaner PCSK9 zur Cholesterinbehandlung |
EP2975059A1 (en) | 2014-07-15 | 2016-01-20 | Kymab Limited | Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations |
US9150660B1 (en) | 2014-07-15 | 2015-10-06 | Kymab Limited | Precision Medicine by targeting human NAV1.8 variants for treatment of pain |
DE202015008974U1 (de) | 2014-07-15 | 2016-06-30 | Kymab Limited | Targeting von humaner PCSK9 zur Cholesterinbehandlung |
KR20170029613A (ko) * | 2014-07-16 | 2017-03-15 | 사노피 바이오테크놀로지 | 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법 |
US20160137746A1 (en) * | 2014-07-16 | 2016-05-19 | Sanofi Biotechnology | Methods for treating high cardiovascular risk patients with hypercholesterolemia |
AR101262A1 (es) | 2014-07-26 | 2016-12-07 | Regeneron Pharma | Plataforma de purificación para anticuerpos biespecíficos |
WO2016020798A1 (en) | 2014-08-06 | 2016-02-11 | Rinat Neuroscience Corp. | Methods for reducing ldl-cholesterol |
WO2016020799A1 (en) | 2014-08-06 | 2016-02-11 | Rinat Neuroscience Corp. | Methods for reducing ldl-cholesterol |
WO2016023916A1 (en) | 2014-08-12 | 2016-02-18 | Kymab Limited | Treatment of disease using ligand binding to targets of interest |
US11554181B2 (en) | 2014-09-05 | 2023-01-17 | The University Of North Carolina At Charlotte | Tumor specific antibody conjugates and uses therefor |
KR20170062466A (ko) | 2014-09-16 | 2017-06-07 | 리제너론 파마슈티칼스 인코포레이티드 | 항-글루카곤 항체 및 그것의 사용 |
EP3197492A1 (en) | 2014-09-23 | 2017-08-02 | Pfizer Inc | Treatment with anti-pcsk9 antibodies |
US10695506B2 (en) | 2014-10-14 | 2020-06-30 | Amgen Inc. | Drug injection device with visual and audio indicators |
AU2015335743B2 (en) | 2014-10-23 | 2020-12-24 | Amgen Inc. | Reducing viscosity of pharmaceutical formulations |
WO2016071701A1 (en) | 2014-11-07 | 2016-05-12 | Kymab Limited | Treatment of disease using ligand binding to targets of interest |
ES2785311T3 (es) | 2014-12-19 | 2020-10-06 | Amgen Inc | Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario |
ES2898469T3 (es) | 2014-12-19 | 2022-03-07 | Amgen Inc | Dispositivo de administración de medicamentos con sensor de proximidad |
CR20170326A (es) | 2014-12-19 | 2017-08-22 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipéptidos que contienen regiones fc variantes, y métodos de uso |
WO2016125495A1 (en) | 2015-02-05 | 2016-08-11 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
CN105461809B (zh) * | 2015-02-11 | 2018-10-12 | 康融东方(广东)医药有限公司 | Pcsk9抗体、其药物组合物及其用途 |
JP6484345B2 (ja) | 2015-02-17 | 2019-03-20 | アムジエン・インコーポレーテツド | 固定及び/または戻りが真空によって支援された薬物送達装置 |
US11806509B2 (en) | 2015-02-27 | 2023-11-07 | Amgen Inc. | Drug delivery device having a needle guard mechanism with a turnable threshold of resistance to needle guard movement |
EP3271405A1 (en) * | 2015-03-20 | 2018-01-24 | Aarhus Universitet | Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders |
EP3297663A4 (en) | 2015-05-18 | 2018-12-19 | Agensys, Inc. | Antibodies that bind to axl proteins |
EP3297662A4 (en) | 2015-05-18 | 2019-03-13 | Agensys, Inc. | ANTIBODY BINDING TO AXL PROTEINS |
CN106084058B (zh) * | 2015-07-15 | 2019-08-27 | 北京天广实生物技术股份有限公司 | 抗人pcsk9单克隆抗体 |
TW202330904A (zh) | 2015-08-04 | 2023-08-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
EP3337828A1 (en) | 2015-08-18 | 2018-06-27 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
WO2017055966A1 (en) | 2015-10-01 | 2017-04-06 | Pfizer Inc. | Low viscosity antibody compositions |
CN106589127A (zh) * | 2015-10-16 | 2017-04-26 | 钜川生物医药 | 一种pcsk9抗体及其制备方法和应用 |
CN105348390B (zh) * | 2015-10-26 | 2018-08-28 | 北京智仁美博生物科技有限公司 | 抗人pcsk9单克隆抗体 |
CN106810609A (zh) * | 2015-11-27 | 2017-06-09 | 苏州君盟生物医药科技有限公司 | 抗pcsk9抗体及其应用 |
US11351308B2 (en) | 2015-12-09 | 2022-06-07 | Amgen Inc. | Auto-injector with signaling cap |
WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
AU2016382932B2 (en) * | 2015-12-31 | 2022-12-08 | Jiangsu Hengrui Medicine Co., Ltd. | PCSK9 antibody, antigen-binding fragment thereof, and medicinal application thereof |
US11154661B2 (en) | 2016-01-06 | 2021-10-26 | Amgen Inc. | Auto-injector with signaling electronics |
MD3416684T2 (ro) * | 2016-02-17 | 2023-10-31 | Regeneron Pharma | Metode de tratament sau prevenire a aterosclerozei prin administrarea unui inhibitor al ANGPTL3 |
MA43734A (fr) | 2016-03-03 | 2018-11-28 | Regeneron Pharma | Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3 |
EP4035711A1 (en) | 2016-03-15 | 2022-08-03 | Amgen Inc. | Reducing probability of glass breakage in drug delivery devices |
US11066464B2 (en) | 2016-03-21 | 2021-07-20 | Kymab Limited | Anti-malarial antibodies that bind circumsporozoite protein |
WO2017163049A1 (en) | 2016-03-21 | 2017-09-28 | Kymab Limited | Anti-malarial antibodies that bind circumsporozoite protein |
CN107266575B (zh) * | 2016-04-07 | 2021-12-24 | 天士力生物医药股份有限公司 | 前蛋白转化酶枯草溶菌素kexin 9型的结合蛋白及其应用 |
US11541168B2 (en) | 2016-04-29 | 2023-01-03 | Amgen Inc. | Drug delivery device with messaging label |
US11389588B2 (en) | 2016-05-02 | 2022-07-19 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
CA3018426A1 (en) | 2016-05-13 | 2017-11-16 | Amgen Inc. | Vial sleeve assembly |
EP3458988B1 (en) | 2016-05-16 | 2023-10-18 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
EP3465124A1 (en) | 2016-06-03 | 2019-04-10 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
CN107474140B (zh) * | 2016-06-08 | 2022-06-03 | 常州博嘉生物医药科技有限公司 | Pcsk9特异性的结合蛋白mv072及其应用 |
WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
WO2018004842A1 (en) | 2016-07-01 | 2018-01-04 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
CA3031542A1 (en) * | 2016-07-20 | 2018-01-25 | University Of Utah Research Foundation | Cd229 car t cells and methods of use thereof |
KR20230079499A (ko) | 2016-08-05 | 2023-06-07 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
US11858996B2 (en) | 2016-08-09 | 2024-01-02 | Kymab Limited | Anti-ICOS antibodies |
WO2018034784A1 (en) | 2016-08-17 | 2018-02-22 | Amgen Inc. | Drug delivery device with placement detection |
WO2018039499A1 (en) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
US20200165354A1 (en) * | 2016-09-20 | 2020-05-28 | WuXi Biologics Ireland Limited | Novel Anti-PCSK9 Antibodies |
US11111313B2 (en) | 2016-09-20 | 2021-09-07 | WuXi Biologics Ireland Limited | Anti-PCSK9 antibodies |
MA46466A (fr) | 2016-10-06 | 2019-08-14 | Amgen Inc | Formulations pharmaceutiques de protéines à viscosité réduite |
WO2018075621A1 (en) * | 2016-10-19 | 2018-04-26 | Vanderbilt University | Human orthopoxvirus antibodies and methods of use therefor |
WO2018075792A1 (en) | 2016-10-20 | 2018-04-26 | Regeneron Pharmaceuticals, Inc. | Methods of lowering blood glucose levels |
WO2018081234A1 (en) | 2016-10-25 | 2018-05-03 | Amgen Inc. | On-body injector |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
JOP20190112A1 (ar) | 2016-11-14 | 2019-05-14 | Amgen Inc | علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي |
CN108239150A (zh) * | 2016-12-24 | 2018-07-03 | 信达生物制药(苏州)有限公司 | 抗pcsk9抗体及其用途 |
AU2018210301A1 (en) | 2017-01-17 | 2019-08-01 | Amgen Inc. | Injection devices and related methods of use and assembly |
CN107698680B (zh) * | 2017-01-22 | 2019-03-01 | 北京东方百泰生物科技有限公司 | 抗pcsk9单克隆抗体 |
CN108424457B (zh) * | 2017-02-13 | 2021-06-01 | 成都金洛克锶生物技术有限公司 | 针对pcsk9抗体与检测试剂盒的制备及其用途 |
MX2019009625A (es) | 2017-02-17 | 2019-10-09 | Amgen Inc | Dispositivo de administracion de farmacos con trayectoria de flujo de fluido esteril y metodo relacionado de ensamblaje. |
US11369736B2 (en) | 2017-02-17 | 2022-06-28 | Amgen Inc. | Cannula insertion and retraction mechanisms |
MX2019010544A (es) | 2017-03-06 | 2019-10-21 | Amgen Inc | Dispositivo de administracion de farmacos con caracteristica de prevencion de la activacion. |
JP2020509839A (ja) | 2017-03-07 | 2020-04-02 | アムジエン・インコーポレーテツド | 超過圧力による針の挿入 |
JP2020509837A (ja) | 2017-03-09 | 2020-04-02 | アムジエン・インコーポレーテツド | 薬剤送達装置のための挿入機構 |
US11957883B2 (en) | 2017-03-28 | 2024-04-16 | Amgen Inc. | Plunger rod and syringe assembly system and method |
US9989519B1 (en) * | 2017-05-04 | 2018-06-05 | Clayton Pharmaceuticals, LLC | Method for determining in vitro bioequivalence of a sucralfate suspension sample to a sucralfate suspension reference listed drug (RLD) |
EP3634546A1 (en) | 2017-06-08 | 2020-04-15 | Amgen Inc. | Torque driven drug delivery device |
CA3061982A1 (en) | 2017-06-08 | 2018-12-13 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
TW202310872A (zh) * | 2017-06-09 | 2023-03-16 | 法商賽諾菲生物技術公司 | 藉由投予pcsk9抑制劑治療糖尿病患者高血脂症之方法 |
US20190031774A1 (en) | 2017-06-09 | 2019-01-31 | Sanofi Biotechnology | Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor |
GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
JP7195276B2 (ja) | 2017-06-22 | 2022-12-23 | アムジエン・インコーポレーテツド | デバイス起動による衝突/衝撃の低減 |
EP3641861A1 (en) | 2017-06-23 | 2020-04-29 | Amgen Inc. | Electronic drug delivery device comprising a cap activated by a switch assembly |
SG11201912548XA (en) | 2017-07-06 | 2020-01-30 | Regeneron Pharma | Cell culture process for making a glycoprotein |
JP7408398B2 (ja) | 2017-07-14 | 2024-01-05 | アムジエン・インコーポレーテツド | 二重ねじりばねシステムを有する針挿入後退システム |
WO2019018169A1 (en) | 2017-07-21 | 2019-01-24 | Amgen Inc. | PERMEABLE GAS SEALING ELEMENT FOR MEDICINE CONTAINER AND METHODS OF ASSEMBLY |
US11617837B2 (en) | 2017-07-25 | 2023-04-04 | Amgen Inc. | Drug delivery device with gear module and related method of assembly |
JP7242562B2 (ja) | 2017-07-25 | 2023-03-20 | アムジエン・インコーポレーテツド | 容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法 |
US20200164155A1 (en) | 2017-08-09 | 2020-05-28 | Amgen Inc. | Hydraulic-pneumatic pressurized chamber drug delivery system |
MA49897A (fr) | 2017-08-18 | 2020-06-24 | Amgen Inc | Injecteur sur-corps avec patch adhésif stérile |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
MA50611A (fr) | 2017-10-04 | 2020-08-12 | Amgen Inc | Adaptateur d'écoulement destiné à un dispositif d'administration de médicament |
EP3691716B1 (en) | 2017-10-06 | 2023-11-29 | Amgen Inc. | Drug delivery device with interlock assembly and related method of assembly |
US11464903B2 (en) | 2017-10-09 | 2022-10-11 | Amgen Inc. | Drug delivery device with drive assembly and related method of assembly |
EP3703779A1 (en) | 2017-11-03 | 2020-09-09 | Amgen Inc. | Systems and approaches for sterilizing a drug delivery device |
US20200261648A1 (en) | 2017-11-06 | 2020-08-20 | Amgen Inc. | Drug delivery device with placement and flow sensing |
EP3707075A1 (en) | 2017-11-06 | 2020-09-16 | Amgen Inc. | Fill-finish assemblies and related methods |
MA50557A (fr) | 2017-11-10 | 2020-09-16 | Amgen Inc | Pistons pour dispositifs d'administration de médicament |
WO2019099322A1 (en) | 2017-11-16 | 2019-05-23 | Amgen Inc. | Autoinjector with stall and end point detection |
WO2019099324A1 (en) | 2017-11-16 | 2019-05-23 | Amgen Inc. | Door latch mechanism for drug delivery device |
GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
WO2019122882A1 (en) | 2017-12-19 | 2019-06-27 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
EP3727629A1 (en) | 2017-12-22 | 2020-10-28 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing drug product impurities |
EA202091689A1 (ru) | 2018-01-31 | 2020-10-22 | Ридженерон Фармасьютикалз, Инк. | Система и способ определения характеристик примесей, представляющих собой варианты, отличающиеся по размеру и заряду, в продукте, представляющем собой лекарственное средство |
US20200362055A1 (en) * | 2018-01-31 | 2020-11-19 | The Wistar Institute Of Anatomy And Biology | Nucleic acid monoclonal antibodies targeting pcsk9 and methods of use |
TWI786265B (zh) | 2018-02-02 | 2022-12-11 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
WO2019165184A1 (en) * | 2018-02-22 | 2019-08-29 | Vanderbilt University | Human japanese encephalitis virus antibodies and methods of use therefor |
WO2019168774A1 (en) | 2018-02-28 | 2019-09-06 | Regeneron Pharmaceuticals, Inc. | Systems and methods for identifying viral contaminants |
RU2020132463A (ru) | 2018-03-06 | 2022-04-06 | Санофи Байотекнолоджи | Применение ингибитора pcsk9 для снижения сердечно-сосудистого риска |
IL307577A (en) | 2018-03-19 | 2023-12-01 | Regeneron Pharma | In-house capillary electrophoresis tests and reagents |
TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
MX2021000163A (es) | 2018-07-02 | 2021-05-27 | Amgen Inc | Proteina de union al antigeno anti-steap1. |
US20210260279A1 (en) | 2018-07-24 | 2021-08-26 | Amgen Inc. | Hybrid drug delivery devices with optional grip portion and related method of preparation |
CN112469454B (zh) | 2018-07-24 | 2024-01-26 | 安进公司 | 用于施用药物的输送装置 |
WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
CA3103682A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
MA53320A (fr) | 2018-07-31 | 2021-11-03 | Amgen Inc | Ensemble de trajet de fluide pour dispositif d'administration de médicament |
BR112020024296A2 (pt) | 2018-08-27 | 2021-03-09 | Regeneron Pharmaceuticals, Inc. | Métodos para produção de um intermediário de purificação de proteína concentrado, para monitoramento e controle dos atributos de qualidade críticos em um intermediário de purificação de proteína e para monitorar e controlar os níveis de excipientes no fluido de cultura de células colhido e/ou intermediário de purificação de proteína, e, intermediário de purificação de proteína |
EA202190032A1 (ru) | 2018-08-30 | 2021-03-12 | Ридженерон Фармасьютикалз, Инк. | Способы определения характеристик белковых комплексов |
CN110872353B (zh) * | 2018-09-03 | 2021-05-04 | 深圳华大基因科技有限公司 | 特异性结合pcsk9抗原的纳米抗体及其制备方法和应用 |
JP2022500095A (ja) | 2018-09-24 | 2022-01-04 | アムジエン・インコーポレーテツド | インターベンション投薬システム及び方法 |
EP3856283A1 (en) | 2018-09-28 | 2021-08-04 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
WO2020072577A1 (en) | 2018-10-02 | 2020-04-09 | Amgen Inc. | Injection systems for drug delivery with internal force transmission |
EP3860686A1 (en) | 2018-10-05 | 2021-08-11 | Amgen Inc. | Drug delivery device having dose indicator |
EP3866889A1 (en) | 2018-10-15 | 2021-08-25 | Amgen Inc. | Platform assembly process for drug delivery device |
AU2019361919A1 (en) | 2018-10-15 | 2021-03-18 | Amgen Inc. | Drug delivery device having damping mechanism |
AU2019369498A1 (en) * | 2018-10-31 | 2021-05-20 | Delinia, Inc. | Multivalent regulatory T cell modulators |
CN111110841A (zh) * | 2018-10-31 | 2020-05-08 | 上海君实生物医药科技股份有限公司 | 含有抗pcsk9抗体的稳定制剂 |
MA54057A (fr) | 2018-11-01 | 2022-02-09 | Amgen Inc | Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament |
WO2020092056A1 (en) | 2018-11-01 | 2020-05-07 | Amgen Inc. | Drug delivery devices with partial needle retraction |
EP3873566A1 (en) | 2018-11-01 | 2021-09-08 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
ES2942024T3 (es) | 2019-01-16 | 2023-05-29 | Regeneron Pharma | Métodos para caracterizar enlaces disulfuro |
CN109734813B (zh) * | 2019-01-28 | 2022-06-17 | 广东昭泰体内生物医药科技有限公司 | 一种嵌合抗原受体及其应用 |
MX2021012557A (es) | 2019-04-24 | 2021-11-12 | Amgen Inc | Conjuntos y metodos de verificacion de esterilizacion de jeringuillas. |
EP3969908A1 (en) | 2019-05-13 | 2022-03-23 | Regeneron Pharmaceuticals, Inc. | Improved competitive ligand binding assays |
EP3969620A1 (en) | 2019-05-17 | 2022-03-23 | Regeneron Pharmaceuticals, Inc. | Genome-based methods for reducing cardiovascular risk |
AU2020337250A1 (en) | 2019-08-23 | 2022-03-03 | Amgen Inc. | Drug delivery device with configurable needle shield engagement components and related methods |
WO2021058597A1 (en) | 2019-09-24 | 2021-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of determining whether a subject is at risk of developing arterial plaques |
CA3216345A1 (en) | 2019-09-24 | 2021-04-01 | Regeneron Pharmaceuticals, Inc. | Systems and methods for chromatography use and regeneration |
CA3158119A1 (en) | 2019-11-25 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
MX2022007071A (es) | 2019-12-10 | 2022-07-11 | Regeneron Pharma | Uso de un inhibidor de pcsk9 para tratar la hipercolesterolemia familiar homocigotica. |
BR112022014212B1 (pt) | 2020-01-21 | 2024-01-23 | Regeneron Pharmaceuticals, Inc | Métodos de análise de uma amostra incluindo uma proteína de interesse |
WO2022031882A1 (en) * | 2020-08-06 | 2022-02-10 | Stelexis Therapeutics, Llc | Il-8 antibodies and methods of use thereof |
AU2021332355A1 (en) | 2020-08-31 | 2023-03-23 | Regeneron Pharmaceuticals, Inc. | Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants |
MX2023006077A (es) | 2020-11-25 | 2023-06-06 | Regeneron Pharma | Formulaciones de liberacion sostenida mediante emulsificacion por membrana no acuosa. |
US20220257707A1 (en) | 2020-12-17 | 2022-08-18 | Regeneron Pharmaceuticals, Inc. | Fabrication of protein-encapsulating microgels |
AU2022209730A1 (en) | 2021-01-20 | 2023-07-13 | Regeneron Pharmaceuticals, Inc. | Methods of improving protein titer in cell culture |
AU2022230987A1 (en) | 2021-03-03 | 2023-08-31 | Regeneron Pharmaceuticals, Inc. | Systems and methods for quantifying and modifying protein viscosity |
BR112023018665A2 (pt) | 2021-03-26 | 2023-10-03 | Regeneron Pharma | Métodos e sistemas para desenvolvimento de protocolos de mistura |
CA3219336A1 (en) | 2021-05-18 | 2022-11-24 | Kymab Limited | Uses of anti-icos antibodies |
WO2022246055A1 (en) | 2021-05-21 | 2022-11-24 | Amgen Inc. | Method of optimizing a filling recipe for a drug container |
TW202314240A (zh) | 2021-06-01 | 2023-04-01 | 美商再生元醫藥公司 | 微晶片毛細管電泳分析及試劑 |
GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
KR20240042267A (ko) | 2021-07-05 | 2024-04-01 | 리제너론 파마슈티칼스 인코포레이티드 | 항원에 대한 항체 반응을 형성하기 위한 항체의 이용 |
TW202326138A (zh) | 2021-09-08 | 2023-07-01 | 美商再生元醫藥公司 | 用於定量抗體及其他含Fc蛋白之高通量及基於質譜之方法 |
CA3232463A1 (en) | 2021-09-20 | 2023-03-23 | Philip Mellors | Methods of controlling antibody heterogeneity |
US20230116199A1 (en) | 2021-10-07 | 2023-04-13 | Regeneron Pharmaceuticals, Inc. | Systems and methods of ph modeling and control |
WO2023059803A1 (en) | 2021-10-07 | 2023-04-13 | Regeneron Pharmaceuticals, Inc. | Ph meter calibration and correction |
WO2023076340A1 (en) | 2021-10-26 | 2023-05-04 | Regeneron Pharmaceuticals, Inc. | Systems and methods for generating laboratory water and distributing laboratory water at different temperatures |
TW202346856A (zh) | 2022-03-18 | 2023-12-01 | 美商里珍納龍藥品有限公司 | 分析多肽變體的方法及系統 |
WO2023222854A1 (en) | 2022-05-18 | 2023-11-23 | Kymab Limited | Uses of anti-icos antibodies |
WO2024040020A1 (en) | 2022-08-15 | 2024-02-22 | Absci Corporation | Quantitative affinity activity specific cell enrichment |
Family Cites Families (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
WO1993000807A1 (en) | 1991-07-03 | 1993-01-21 | Cryolife, Inc. | Method for stabilization of biomaterials |
WO1993022336A1 (en) | 1992-04-30 | 1993-11-11 | Alpha Therapeutic Corporation | Improved solubilization and stabilization of factor viii complex |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
GB9410534D0 (en) | 1994-05-26 | 1994-07-13 | Lynxvale Ltd | Improvements in or relating to growth factor inhibitors |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
JPH09154588A (ja) | 1995-10-07 | 1997-06-17 | Toagosei Co Ltd | Vegf結合性ポリペプチド |
WO1997035620A1 (en) | 1996-03-26 | 1997-10-02 | Eli Lilly And Company | Formulations of ob protein |
US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
US7312196B2 (en) | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
US20070224663A1 (en) | 1997-03-07 | 2007-09-27 | Human Genome Sciences, Inc. | Human Secreted Proteins |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US6187330B1 (en) | 1998-01-30 | 2001-02-13 | Scios Inc. | Controlled release delivery of peptide or protein |
US7001892B1 (en) | 1999-06-11 | 2006-02-21 | Purdue Research Foundation | Pharmaceutical materials and methods for their preparation and use |
EP1067182A3 (en) | 1999-07-08 | 2001-11-21 | Helix Research Institute | Secretory protein or membrane protein |
US7129338B1 (en) * | 1999-07-08 | 2006-10-31 | Research Association For Biotechnology | Secretory protein or membrane protein |
US7029895B2 (en) | 1999-09-27 | 2006-04-18 | Millennium Pharmaceuticals, Inc. | 27411, a novel human PGP synthase |
EP1257572A2 (en) | 2000-02-07 | 2002-11-20 | Millennium Pharmaceuticals, Inc. | Narc-1, subtilase-like homologs |
US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
DK1317537T3 (da) | 2000-09-08 | 2007-04-30 | Massachusetts Inst Technology | Sammensætninger og fremgangsmåder med G-CSF analoger |
EP1324776B2 (en) | 2000-10-12 | 2018-03-21 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
WO2003009817A2 (en) | 2001-07-25 | 2003-02-06 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
WO2004055164A2 (en) | 2002-12-13 | 2004-07-01 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
LT2335725T (lt) | 2003-04-04 | 2017-01-25 | Genentech, Inc. | Didelės koncentracijos antikūno ir baltymo kompozicijos |
EP1471152A1 (en) | 2003-04-25 | 2004-10-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Mutations in the human PCSK9 gene associated to hypercholesterolemia |
EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
US20060147945A1 (en) | 2005-01-06 | 2006-07-06 | Edmonds Brian T | Novel secreted proteins and their uses |
AU2007258117B2 (en) | 2006-05-05 | 2013-05-30 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating gene expression |
CN101489565A (zh) | 2006-05-05 | 2009-07-22 | Isis药物公司 | 调节pcsk9表达的化合物和方法 |
CA2652976C (en) | 2006-06-02 | 2015-08-11 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human il-6 receptor |
MX2008016124A (es) | 2006-06-16 | 2009-01-20 | Regeneron Pharma | Formulaciones antagonistas de vegf adecuadas para la administracion intravitreal. |
US7572618B2 (en) * | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
EP2083859A4 (en) | 2006-11-07 | 2010-11-24 | Merck Sharp & Dohme | ANTAGONISTS OF PCSK9 |
WO2008057459A2 (en) | 2006-11-07 | 2008-05-15 | Merck & Co., Inc. | Antagonists of pcsk9 |
CA2667989A1 (en) | 2006-11-07 | 2008-11-06 | Merck & Co., Inc. | Antagonists of pcsk9 |
US20100150937A1 (en) | 2006-11-07 | 2010-06-17 | Sparrow Carl P | Antagonists of pcsk9 |
US8093222B2 (en) | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
EP2455471A3 (en) | 2006-11-27 | 2012-09-12 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
TW200906439A (en) | 2007-04-13 | 2009-02-16 | Novartis Ag | Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (PCSK9) |
CN101687927B (zh) | 2007-05-15 | 2013-10-30 | 霍夫曼-拉罗奇有限公司 | 针对g蛋白偶联的受体(gpcr)的抗体 |
JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
WO2009042765A1 (en) | 2007-09-25 | 2009-04-02 | The Regents Of The University Of California | Methods of modulating prokineticin 2 for treatment of stress response and anxiety-related disorders |
CN102232088A (zh) | 2007-10-26 | 2011-11-02 | 先灵公司 | 用于治疗脂类和胆固醇疾病的抗pcsk9及方法 |
AR070316A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
AR070315A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
SG189775A1 (en) | 2008-04-11 | 2013-05-31 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
TWI516501B (zh) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9拮抗劑類 |
ES2658596T3 (es) | 2008-09-19 | 2018-03-12 | Pfizer Inc. | Formulación líquida estable de anticuerpos |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
WO2010068526A1 (en) | 2008-12-12 | 2010-06-17 | Merck Sharp & Dohme Corp. | Pcsk9 immunoassay |
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
US8357371B2 (en) | 2008-12-15 | 2013-01-22 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to PCSK9 |
CN102414221A (zh) | 2009-03-06 | 2012-04-11 | 健泰科生物技术公司 | 抗体配制剂 |
KR20120027031A (ko) | 2009-06-18 | 2012-03-20 | 와이어쓰 엘엘씨 | 소형 모듈 면역제약용 동결건조 제제 |
WO2011028938A1 (en) | 2009-09-02 | 2011-03-10 | Alnylam Pharmaceuticals, Inc. | Methods for lowering serum cholestrol in a subject using inhibition of pcsk9 |
EP2480576A4 (en) | 2009-09-25 | 2013-04-10 | Merck Sharp & Dohme | ANTAGONISTS OF PCSK9 |
WO2011039578A1 (en) | 2009-10-02 | 2011-04-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination of spla2 activity and lp(a) cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event |
IN2012DN03824A (lt) | 2009-10-30 | 2015-08-28 | Merck Sharp & Dohme | |
AU2010313381A1 (en) | 2009-10-30 | 2012-04-12 | Merck Sharp & Dohme Corp. | AX1 and AX189 PCSK9 antagonists and variants |
PT3721904T (pt) | 2009-11-20 | 2021-11-15 | Biocon Ltd | Formulações de anticorpo t1h |
AR079336A1 (es) | 2009-12-11 | 2012-01-18 | Irm Llc | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) |
JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
CN102844332B (zh) | 2010-03-11 | 2015-08-19 | 瑞纳神经科学公司 | 呈pH依赖性抗原结合的抗体 |
GB201005005D0 (en) | 2010-03-25 | 2010-05-12 | Angeletti P Ist Richerche Bio | New vaccine |
WO2012044999A2 (en) * | 2010-10-01 | 2012-04-05 | Ludwig Institute For Cancer Research Ltd. | Reversible protein multimers, methods for their production and use |
CA2813587C (en) | 2010-10-06 | 2019-01-15 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
WO2012054438A1 (en) | 2010-10-22 | 2012-04-26 | Schering Corporation | Anti-pcsk9 |
CN103328514B (zh) | 2010-11-09 | 2015-12-02 | 阿尔蒂单抗治疗公司 | 用于抗原结合的蛋白复合物及其使用方法 |
US8771696B2 (en) * | 2010-11-23 | 2014-07-08 | Regeneron Pharmaceuticals, Inc. | Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor |
JO3756B1 (ar) * | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
SG191219A1 (en) | 2010-12-22 | 2013-07-31 | Genentech Inc | Anti-pcsk9 antibodies and methods of use |
MX347602B (es) | 2011-01-28 | 2017-05-03 | Sanofi Biotechnology | Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9. |
WO2012109530A1 (en) | 2011-02-11 | 2012-08-16 | Irm Llc | Pcsk9 antagonists |
AR088782A1 (es) | 2011-04-29 | 2014-07-10 | Sanofi Sa | Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes |
JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
US20140004122A1 (en) | 2011-05-10 | 2014-01-02 | Amgen Inc. | Methods for treating or preventing cholesterol related disorders |
CA2840482C (en) | 2011-07-14 | 2018-10-16 | Pfizer Inc. | Treatment with anti-pcsk9 antibodies |
AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
JP6158813B2 (ja) | 2011-09-16 | 2017-07-05 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | プロタンパク質転換酵素サブチリシンケキシン−9(PCSK9)の阻害剤を投与することによってリポタンパク質(a)レベルを低下させる方法 |
AR087715A1 (es) | 2011-09-16 | 2014-04-09 | Lilly Co Eli | Anticuerpos anti pcsk9 y usos de los mismos |
JP2015515279A (ja) | 2012-04-19 | 2015-05-28 | アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. | 治療に反応する患者を同定するバイオマーカーおよびそのような患者の治療 |
EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
EP3210972A1 (en) | 2012-05-25 | 2017-08-30 | Catabasis Pharmaceuticals, Inc. | Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9) |
EA028244B1 (ru) * | 2012-08-13 | 2017-10-31 | Ридженерон Фармасьютикалз, Инк. | АНТИТЕЛА К PCSK9 C pH-ЗАВИСИМЫМИ ХАРАКТЕРИСТИКАМИ СВЯЗЫВАНИЯ |
EP2703009A1 (en) | 2012-08-31 | 2014-03-05 | Sanofi | Combination treatments involving antibodies to human PCSK9 |
EP2703008A1 (en) | 2012-08-31 | 2014-03-05 | Sanofi | Human antibodies to PCSK9 for use in methods of treating particular groups of subjects |
EP2706070A1 (en) | 2012-09-06 | 2014-03-12 | Sanofi | Combination treatments involving antibodies to human PCSK9 |
US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
TWI682780B (zh) | 2013-05-30 | 2020-01-21 | 美商再生元醫藥公司 | 醫藥組成物用於製造治療與pcsk9功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途 |
TW202021614A (zh) | 2013-06-07 | 2020-06-16 | 法商賽諾菲生物技術公司 | 藉由投與pcsk9抑制劑抑制動脈粥狀硬化的方法 |
JP6846931B2 (ja) | 2013-10-11 | 2021-03-24 | サノフィ・バイオテクノロジー | 高脂血症を処置するためのpcsk9阻害剤の使用 |
EP3068803B1 (en) | 2013-11-12 | 2021-01-20 | Sanofi Biotechnology | Dosing regimens for use with pcsk9 inhibitors |
US9034332B1 (en) * | 2014-07-15 | 2015-05-19 | Kymab Limited | Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment |
US8945560B1 (en) | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
US8883157B1 (en) * | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
CN106029096A (zh) | 2014-02-14 | 2016-10-12 | 瑞泽恩制药公司 | 用于治疗具有未被中等剂量他汀疗法充分控制的高胆固醇血症的患者的方法 |
WO2015140079A1 (en) | 2014-03-17 | 2015-09-24 | Sanofi | Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled |
MX2016011975A (es) | 2014-03-17 | 2016-12-05 | Sanofi Biotechnology | Metodos para reducir el riesgo cardiovascular. |
KR20170029613A (ko) * | 2014-07-16 | 2017-03-15 | 사노피 바이오테크놀로지 | 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법 |
US20160137746A1 (en) | 2014-07-16 | 2016-05-19 | Sanofi Biotechnology | Methods for treating high cardiovascular risk patients with hypercholesterolemia |
EP3337828A1 (en) | 2015-08-18 | 2018-06-27 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis |
US10933134B2 (en) | 2017-03-16 | 2021-03-02 | Memorial Sloan Kettering Cancer Center | Combination therapies for treatment of cancer |
-
2009
- 2009-12-14 JO JOP/2009/0481A patent/JO3672B1/ar active
- 2009-12-15 DK DK16200305.7T patent/DK3156422T3/da active
- 2009-12-15 EP EP16200305.7A patent/EP3156422B1/en active Active
- 2009-12-15 HR HRP20170488TT patent/HRP20170488T4/hr unknown
- 2009-12-15 TW TW098142896A patent/TWI465249B/zh active
- 2009-12-15 EP EP21185555.6A patent/EP3943510A3/en active Pending
- 2009-12-15 ME MEP-2017-70A patent/ME02760B/me unknown
- 2009-12-15 MX MX2014004581A patent/MX341041B/es unknown
- 2009-12-15 CN CN201410749251.XA patent/CN104447997A/zh active Pending
- 2009-12-15 ES ES09793408T patent/ES2613489T5/es active Active
- 2009-12-15 PL PL16200305T patent/PL3156422T3/pl unknown
- 2009-12-15 LT LTEP09793408.7T patent/LT2358756T/lt unknown
- 2009-12-15 PL PL09793408.7T patent/PL2358756T5/pl unknown
- 2009-12-15 PA PA20098854201A patent/PA8854201A1/es unknown
- 2009-12-15 KR KR1020157001056A patent/KR101699707B1/ko active IP Right Grant
- 2009-12-15 KR KR1020117013676A patent/KR101504494B1/ko active IP Right Grant
- 2009-12-15 RS RS20211437A patent/RS62580B1/sr unknown
- 2009-12-15 DK DK09793408.7T patent/DK2358756T4/da active
- 2009-12-15 AU AU2009333326A patent/AU2009333326B9/en active Active
- 2009-12-15 PT PT97934087T patent/PT2358756T/pt unknown
- 2009-12-15 WO PCT/US2009/068013 patent/WO2010077854A1/en active Application Filing
- 2009-12-15 MX MX2011006197A patent/MX2011006197A/es active IP Right Grant
- 2009-12-15 HU HUE09793408A patent/HUE032681T2/en unknown
- 2009-12-15 UY UY0001032329A patent/UY32329A/es not_active Application Discontinuation
- 2009-12-15 HR HRP20211688TT patent/HRP20211688T1/hr unknown
- 2009-12-15 RS RS20170255A patent/RS55771B2/sr unknown
- 2009-12-15 CA CA2747123A patent/CA2747123C/en active Active
- 2009-12-15 PT PT162003057T patent/PT3156422T/pt unknown
- 2009-12-15 NZ NZ593155A patent/NZ593155A/xx unknown
- 2009-12-15 EP EP09793408.7A patent/EP2358756B2/en active Active
- 2009-12-15 ES ES16200305T patent/ES2898661T3/es active Active
- 2009-12-15 UA UAA201108829A patent/UA105650C2/uk unknown
- 2009-12-15 PE PE2011001214A patent/PE20120014A1/es active IP Right Grant
- 2009-12-15 SI SI200932149T patent/SI3156422T1/sl unknown
- 2009-12-15 JP JP2011540965A patent/JP5318965B2/ja active Active
- 2009-12-15 RU RU2015109166A patent/RU2697773C2/ru active
- 2009-12-15 CN CN200980150206.XA patent/CN102245641B/zh active Active
- 2009-12-15 US US12/637,942 patent/US8062640B2/en active Active
- 2009-12-15 AR ARP090104880A patent/AR077724A1/es active IP Right Grant
- 2009-12-15 LT LTEP16200305.7T patent/LT3156422T/lt unknown
- 2009-12-15 ME MEP-2011-111A patent/ME01327B/me unknown
- 2009-12-15 HU HUE16200305A patent/HUE056244T2/hu unknown
- 2009-12-15 RU RU2011129316A patent/RU2552169C3/ru active Protection Beyond IP Right Term
- 2009-12-15 NZ NZ601923A patent/NZ601923A/xx unknown
- 2009-12-15 SI SI200931637T patent/SI2358756T2/sl unknown
-
2010
- 2010-11-19 US US12/949,846 patent/US8501184B2/en active Active
-
2011
- 2011-05-22 IL IL213050A patent/IL213050A/en active IP Right Grant
- 2011-05-23 ZA ZA2011/03762A patent/ZA201103762B/en unknown
- 2011-06-02 CR CR20110296A patent/CR20110296A/es unknown
- 2011-06-06 NI NI201100111A patent/NI201100111A/es unknown
- 2011-06-13 TN TN2011000300A patent/TN2011000300A1/fr unknown
- 2011-06-13 DO DO2011000184A patent/DOP2011000184A/es unknown
- 2011-06-14 CO CO11073672A patent/CO6571847A2/es active IP Right Grant
- 2011-06-14 HN HN2011001659A patent/HN2011001659A/es unknown
- 2011-06-15 EC EC2011011134A patent/ECSP11011134A/es unknown
-
2012
- 2012-11-30 US US13/690,585 patent/US20130085266A1/en not_active Abandoned
-
2013
- 2013-04-19 JP JP2013088230A patent/JP5902122B2/ja active Active
-
2014
- 2014-02-02 IL IL230771A patent/IL230771A/en active IP Right Grant
-
2015
- 2015-06-12 US US14/737,488 patent/US9550837B2/en active Active
-
2016
- 2016-12-13 US US15/377,364 patent/US10023654B2/en active Active
-
2017
- 2017-03-10 CY CY20171100308T patent/CY1118896T1/el unknown
- 2017-06-16 NL NL300879C patent/NL300879I2/nl unknown
- 2017-06-19 CY CY2017021C patent/CY2017021I2/el unknown
- 2017-06-19 LT LTPA2017019C patent/LTC2358756I2/lt unknown
- 2017-06-21 LU LU00024C patent/LUC00024I2/en unknown
- 2017-06-21 FR FR17C1022C patent/FR17C1022I2/fr active Active
- 2017-06-27 NO NO2017029C patent/NO2017029I2/no unknown
- 2017-06-27 HU HUS1700029C patent/HUS1700029I1/hu unknown
- 2017-07-03 FI FIEP09793408.7T patent/FI2358756T4/fi active
- 2017-07-03 FI FIC20170031C patent/FIC20170031I1/fi unknown
-
2018
- 2018-06-04 US US15/996,773 patent/US10941210B2/en active Active
-
2021
- 2021-01-28 US US17/160,634 patent/US20210253735A1/en not_active Abandoned
-
2023
- 2023-04-05 US US18/296,265 patent/US20230340153A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LTPA2017019I1 (lt) | Žmogaus antikūnai, pasižymintys dideliu giminingumu PCSK9 | |
CY2019004I2 (el) | Τροποποιημενα αντισωματα αντι-ιl-23ρ19 | |
CY2018003I1 (el) | Ανθρωπινα αντισωματα υψηλης συγγενειας εναντιον ανθρωπινου υποδοχεα il-4 | |
NO2021006I1 (no) | Quofenix, delafloksacin | |
BRPI0906877A2 (pt) | Anticorpos anti-trkb aperfeiçoados | |
BRPI0922800A2 (pt) | anticorpos c-met | |
BRPI0907237A2 (pt) | Anticorpo anti-cldn6 | |
PL2354161T3 (pl) | Przeciwciało anty -NR10 i jego zastosowanie | |
BRPI0807991A2 (pt) | Anticorpos anti-il-23r elaborados. | |
BRPI0909633A2 (pt) | anticorpos anti-tyrp1 | |
BRPI0912769A2 (pt) | anticorpos anti-pirb | |
SI2354161T1 (sl) | Anti-NR10 protitelo in njegova uporaba | |
BRPI0822637A2 (pt) | Uso de lanosta-8, 24-dien-3-óis | |
FI20095189A (fi) | Henkilönostimen tikkaat, henkilönostin sekä menetelmä henkilönostimen tikkaiden käyttämiseksi | |
TH128473B (th) | แอนติ-il-13 แอนติบอดี ที่ได้รับการจัดการ องค์ประกอบ วิธีและการใช้ | |
BRPI0909770A2 (pt) | Vacina, e, kit | |
UA17814S (uk) | Тролейбус | |
TH110392B (th) | แอนติบอดีสองจำเพาะ, ชนิดไบวาเลนท์ | |
ITPR20080004A1 (it) | Seggiola. | |
EA202091305A3 (ru) | Белки на основе структурного домена фибронектина, связывающие pcsk9 | |
IT1391561B1 (it) | Seggiolone con altalena | |
TH100148B (th) | ที่วางแขน |